Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 12/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17108650 | 0.86 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL2608963 | 0.86 | CYP2D6 (0.43) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL25917688 | 0.84 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL24235262 | 0.84 | CYP2D6 (0.55) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL26184568 | 0.84 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL18926689 | 0.82 | CYP2D6 (0.68) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 | |
| SCHEMBL24616015 | 0.81 | DRD2 (0.37) | CYP2D6SMN1; SMN2 | |
| SCHEMBL24616098 | 0.81 | DRD2 (0.37) | CYP2D6SMN1; SMN2 | |
| SCHEMBL4323995 | 0.81 | CYP2D6 (0.35) | CYP2D6SMN1; SMN2 | |
| SCHEMBL23740954 | 0.81 | CYP2D6 (0.43) | CYP2D6SMN1; SMN2PIK3CDALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2023220741-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | DICE MOLECULES SV, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023212240-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11746110-B2 | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2023-09-05 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8158625-B2 | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-20100305084-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | HOFFMAN-LA ROCHE INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | CYP2D6 4860/4885SMN1; SMN2 651/4885PIK3CD 162/4885 |
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2B | CYP2D6 308/4885SMN1; SMN2 3866/4885PIK3CD 1553/4885 |
| US-20100305084-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PI4K2B, PIK3CA, PIK3R2 | CYP2D6 2177/4885SMN1; SMN2 3259/4885PIK3CD 4/4885 |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | CYP2D6 2699/4885SMN1; SMN2 2134/4885PIK3CD 3/4885 |
| US-11746110-B2 | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity | ALK, WEE1, WEE2 | CYP2D6 844/4885SMN1; SMN2 4786/4885PIK3CD 423/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | CYP2D6 1897/4885SMN1; SMN2 4150/4885PIK3CD 2669/4885 |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | CYP2D6 210/4885SMN1; SMN2 4370/4885PIK3CD 2179/4885 |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT1, WNT3, WNT3A | CYP2D6 2778/4885SMN1; SMN2 2736/4885PIK3CD 843/4885 |
| US-20080045516-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | CYP2D6 465/4885SMN1; SMN2 4053/4885PIK3CD 2040/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | CYP2D6 2614/4885SMN1; SMN2 2248/4885PIK3CD 3/4885 |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | CYP2D6 995/4885SMN1; SMN2 3309/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.